BioSpace News Archive

CAPS Medical, developer of a highly selective and minimally invasive non-thermal plasma device for cancer treatment, announced the enrollment of the first patients in a multi-center study to assess the safety and technical performance of their NTAP™ system in the treatment of Non Muscle Invasive Bladder Cancer.

Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the European Commission (EC) approval of Filsuvez® in the European Union (EU) for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older.

Cingulate Inc. today announced completion of the formulation study for its third asset, CTx-2103, for the management of anxiety-related disorders.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company.

RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, today announced that it will present preclinical data for OTX-2002 Conference.

Ad-Tech Medical, an ArchiMed portfolio company, and the country’s leading manufacturer of neuro electrodes today announced that Joshua Rodebaugh has joined the company’s clinical support and sales team.

Cognition Therapeutics , Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB).

InvoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited and F-star Therapeutics, Inc. today announced that the companies have entered into a definitive agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share.

Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise interval.